Cytokinetics (CYTK) Non-Current Debt (2010 - 2026)
Cytokinetics (CYTK) posted quarterly Non-Current Debt of $247.2 million for Q1 2026, up 168.63% year-over-year from $92.0 million in Q1 2025, and little changed quarter-over-quarter from $246.4 million in Q4 2025.
Cytokinetics (CYTK) Non-Current Debt (2010 - 2026) Analysis & Trends
Cytokinetics (CYTK) has reported Non-Current Debt for 13 consecutive years, with $247.2 million the latest figure, recorded in Q1 2026.
- In Q1 2026, Non-Current Debt rose 168.63% year-over-year to $247.2 million; the TTM figure through Mar 2026 stood at $247.2 million (up 168.63% YoY), while the FY2025 annual figure was $246.4 million, up 164.28% from the prior year.
- Non-Current Debt was little changed at $247.2 million in Q1 2026 per CYTK's latest filing, from $246.4 million in the prior quarter.
- Across five years, Non-Current Debt topped out at $247.2 million in Q1 2026 and bottomed at $56.8 million in Q1 2024.
- Historically, Non-Current Debt has averaged $102.1 million across 5 years, with a median of $64.1 million in 2023.
- Annual changes were most pronounced in 2024 — Non-Current Debt decreased 11.37% — and 2026, when it soared 168.63%.
- Cytokinetics' Non-Current Debt stood at $63.8 million in 2022, then declined by 8.5% to $58.4 million in 2023, then jumped by 59.68% to $93.2 million in 2024, then jumped by 164.28% to $246.4 million in 2025, then rose by 0.33% to $247.2 million in 2026.
- Business Quant data shows CYTK's Non-Current Debt at $247.2 million in Q1 2026, $246.4 million in Q4 2025, and $158.7 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Non-Current Debt (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | - |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 1.99 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | - |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | - |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 882.16 Mn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | - |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 8.96 Bn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | - |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 546.77 Mn |
| 10 | Cytokinetics | 10.31 Bn | 9.14 Bn | 25.89 Mn | 248.20 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 248.20 Mn |
| Mar 31, 2026 | 247.21 Mn |
| Dec 31, 2025 | 246.38 Mn |
| Sep 30, 2025 | 158.75 Mn |
| Jun 30, 2025 | 159.06 Mn |
| Mar 31, 2025 | 92.03 Mn |
| Dec 31, 2024 | 93.23 Mn |
| Sep 30, 2024 | 93.02 Mn |
| Jun 30, 2024 | 92.83 Mn |
| Mar 31, 2024 | 56.82 Mn |
| Dec 31, 2023 | 58.38 Mn |
| Sep 30, 2023 | 60.89 Mn |
| Jun 30, 2023 | 62.49 Mn |
| Mar 31, 2023 | 64.11 Mn |
| Dec 31, 2022 | 63.81 Mn |
| Sep 30, 2022 | 63.54 Mn |
| Jun 30, 2022 | 62.34 Mn |
| Mar 31, 2022 | 61.17 Mn |
| Dec 31, 2021 | 47.37 Mn |
| Sep 30, 2021 | 30.20 Mn |